Acute Gastritis Differential Diagnoses

1. Shimony S, Reiss Mintz H, Shvartser Beryozkin Y, Shoham A, Raanani P, Wolach O. Necrotizing hemorrhagic gastritis following acute myeloid leukemia induction with midostaurin: an unexpected complication. Acta Haematol. 2020. 143(1):65-8. [QxMD MEDLINE Link].

2. Chen D, Zhao R, Cao W, et al. Clinical characteristics of cytomegalovirus gastritis: A retrospective study from a tertiary medical center. Medicine (Baltimore). 2020 Jan. 99(5):e18927. [QxMD MEDLINE Link]. [Full Text].

3. Yamamoto S, Sakai Y. Acute gastritis caused by concurrent infection with Epstein-Barr virus and cytomegalovirus in an immunocompetent adult. Clin J Gastroenterol. 2019 Jun. 12(3):274-8. [QxMD MEDLINE Link].

4. Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica. 2019 Sep. 111(3):92-7. [QxMD MEDLINE Link]. [Full Text].

5. Siregar GA, Siregar GP Darmadi D. Gastrointestinal aspects of COVID-19: a review. Open Access Maced J Med Sci [Internet]. 2020 Jun 20. 8(T1):52-5. [Full Text].

6. Martin TA, Wan DW, Hajifathalian K, Tewani S, Shah SL, Mehta A, et al. Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A Matched Case-Control Study. Am J Gastroenterol. 2020 Oct. 115 (10):1609-1616. [QxMD MEDLINE Link].

7. Trindade AJ, Izard S, Coppa K, et al, for the Northwell COVID-19 Research Consortium. Gastrointestinal bleeding in hospitalized COVID-19 patients: a propensity score matched cohort study. J Intern Med. 2021 Jun. 289(6):887-94. [QxMD MEDLINE Link]. [Full Text].

8. Hunt RH, East JE, Lanas A, et al. COVID-19 and gastrointestinal disease: implications for the gastroenterologist. Dig Dis. 2021. 39(2):119-39. [QxMD MEDLINE Link]. [Full Text].

9. Sonkar C, Kashyap D, Varshney N, Baral B, Jha HC. Impact of gastrointestinal symptoms in COVID-19: a molecular approach. SN Compr Clin Med. 2020 Nov 4. 1-12. [QxMD MEDLINE Link]. [Full Text].

10. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7. 382(19):1787-99. [QxMD MEDLINE Link]. [Full Text].

11. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr. 2016 Jan. 62(1):36-42. [QxMD MEDLINE Link].

12. Biecker E. Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. World J Gastrointest Pharmacol Ther. 2015 Nov 6. 6(4):172-82. [QxMD MEDLINE Link].

13. [Guideline] Park WG, Shaheen NJ, Cohen J, et al. Quality indicators for EGD. Gastrointest Endosc. 2015 Jan. 81(1):17-30. [QxMD MEDLINE Link]. [Full Text].

14. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010 Oct. 8(10):830-7, 837.e1-2. [QxMD MEDLINE Link].

15. Saltzman JR. Hemostatic spray for the management of gastrointestinal bleeding. Gastroenterol Hepatol (N Y). 2019 Jan. 15(1):40-3. [QxMD MEDLINE Link]. [Full Text].

16. Ali Khan M, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol Hepatol (N Y). 2018 Mar. 14(3):169-75. [QxMD MEDLINE Link]. [Full Text].

17. Bramhall SR, Mourad MM. Is there still a role for sucralfate in the treatment of gastritis?. World J Metaanal. 2020 Feb 28. 8(1):1-3. [Full Text].

18. Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis. 2020 Dec. 52(12):1410-2. [QxMD MEDLINE Link]. [Full Text].

19. Lee SW, Ha EK, Yeniova AO, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021 Jan. 70(1):76-84. [QxMD MEDLINE Link]. [Full Text].

20. Lee SW, Yang JM, Yoo IK, et al. Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort. Gut. 2021. 70(10):2013-5. [QxMD MEDLINE Link]. [Full Text].

21. Price E. Could the severity of COVID-19 be increased by low gastric acidity?. Crit Care. 2020 Jul 22. 24(1):456. [QxMD MEDLINE Link]. [Full Text].

22. Freedberg DE, Conigliaro J, Wang TC, et al, for the Famotidine Research Group. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020 Sep. 159(3):1129-31.e3. [QxMD MEDLINE Link]. [Full Text].

23. US Food and Drug Administration. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine [news release]. September 13, 2019. Available at http://fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine.

24. US Food and Drug Administration. FDA requests removal of all ranitidine products (Zantac) from the market [news release]. April 1, 2020. Available at http://fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.

25. [Guideline] Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb. 112(2):212-39. [QxMD MEDLINE Link]. [Full Text].

26. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28. CD009034. [QxMD MEDLINE Link]. [Full Text].

27. Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond). 2020 Jun. 52(6):381-90. [QxMD MEDLINE Link].

28. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov. 32(10):1240-8. [QxMD MEDLINE Link].

29. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors--where do we stand in 2012?. World J Gastroenterol. 2012 May 14. 18(18):2161-71. [QxMD MEDLINE Link].

30. Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012 Jul. 33(5):278-83. [QxMD MEDLINE Link].

31. Pang J, Wu Q, Zhang Z, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019 Jun. 23:100317. [QxMD MEDLINE Link]. [Full Text].

32. Andreev DN, Maev IV, Dicheva DT. Efficiency of the inclusion of rebamipide in the eradication therapy for Helicobacter pylori infection: meta-analysis of randomized controlled studies. J Clin Med. 2019 Sep 19. 8(9):1498. [QxMD MEDLINE Link]. [Full Text].

33. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis. Dig Dis Sci. 2018 May. 63(5):1250-60. [QxMD MEDLINE Link].

34. Ishida M, Tsuchiya M, Naito J, et al. Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports. Kidney Int. 2022 Sep. 102 (3):666-8. [QxMD MEDLINE Link]. [Full Text].

35. Zhang M, Xiao Y, Chen M. The role of vonoprazan in patients with erosive esophagitis. Therap Adv Gastroenterol. 2022. 15:17562848221122623. [QxMD MEDLINE Link].

36. Phathom Pharmaceuticals. Phathom Pharmaceuticals provides update on new drug application review of vonoprazan for erosive esophagitis. Available at https://www.globenewswire.com/news-release/2023/01/03/2582483/0/en/Phathom-Pharmaceuticals-Provides-Update-on-New-Drug-Application-Review-of-Vonoprazan-for-Erosive-Esophagitis.html. January 3, 2023; Accessed: February 3, 2023.

37. Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-Based Triple Therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019. 2019:9781212. [QxMD MEDLINE Link].

38. Shehryar M, Ahmad RU, Kareem HK, et al. Efficacy, safety and cost-effectiveness of vonoprazan vs proton pump Inhibitors in reflux disorders and H pylori eradication: a literature review. Ann Med Surg (Lond). 2022 Oct. 82:104760. [QxMD MEDLINE Link].

39. Ang D, Koo SH, Chan YH, et al. Clinical trial: seven-day vonoprazan versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022 Aug. 56 (3):436-49. [QxMD MEDLINE Link].

40. Shinozaki S, Osawa H, Miura Y, et al. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'. Biomed Rep. 2022 Jun. 16 (6):51. [QxMD MEDLINE Link].

41. [Guideline] Georgopoulos SD, Michopoulos S, Rokkas T, et al. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol. 2020 Mar-Apr. 33(2):105-24. [QxMD MEDLINE Link]. [Full Text].

42. [Guideline] Centers for Disease Control and Prevention. Tuberculosis (TB): treatment for TB disease. Available at http://cdc.gov/tb/topic/treatment/tbdisease.htm. Reviewed: April 5, 2016; Accessed: July 13, 2020.

43. Sonnenberg A, Genta RM. Inverse association between Helicobacter pylori gastritis and microscopic colitis. Inflamm Bowel Dis. 2016 Jan. 22(1):182-6. [QxMD MEDLINE Link].

44. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006 Nov 15. 24(10):1469-74. [QxMD MEDLINE Link].

45. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006 Mar. 101(3):488-96. [QxMD MEDLINE Link].

46. Andersen LP. Colonization and infection by Helicobacter pylori in humans. Helicobacter. 2007 Nov. 12 Suppl 2:12-5. [QxMD MEDLINE Link].

47. Beers M, Berkow R, eds. Gastritis. The Merck Manual of Diagnosis and Therapy. 18th ed. 2006. Section 3, Chapter 23.

48. Lee EL, Feldman M. Gastritis and other gastropathies. Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders; 2002. 810-27.

49. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004 Oct 18. CD003840. [QxMD MEDLINE Link].

50. Gelfand DW, Ott DJ, Chen MY. Radiologic evaluation of gastritis and duodenitis. AJR Am J Roentgenol. 1999 Aug. 173(2):357-61. [QxMD MEDLINE Link].

51. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am J Gastroenterol. 2001 Oct. 96(10):2829-38. [QxMD MEDLINE Link].

52. Haruma K. Helicobacter heilmannii: a spiral shaped organism other than Helicobacter pylori. Intern Med. 1999 Mar. 38(3):217-8. [QxMD MEDLINE Link].

53. Ikenberry SO, Harrison ME, Lichtenstein D, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2007 Dec. 66(6):1071-5. [QxMD MEDLINE Link].

54. Iwakiri Y, Kabemura T, Yasuda D, et al. A case of acute phlegmonous gastritis successfully treated with antibiotics. J Clin Gastroenterol. 1999 Mar. 28(2):175-7. [QxMD MEDLINE Link].

55. Kasper DL, Braunwald E, Fauci A, et al. Gastritis. Harrison's Principles of Internal Medicine: Companion Handbook. 16th ed. McGraw-Hill: 2006. Part 12, Chapter 274.

56. Richieri JP, Pol B, Payan MJ. Acute necrotizing ischemic gastritis: clinical, endoscopic and histopathologic aspects. Gastrointest Endosc. 1998 Aug. 48(2):210-2. [QxMD MEDLINE Link].

57. Soltermann A, Koetzer S, Eigenmann F, et al. Correlation of Helicobacter pylori virulence genotypes vacA and cagA with histological parameters of gastritis and patient's age. Mod Pathol. 2007 Aug. 20(8):878-83. [QxMD MEDLINE Link]. [Full Text].

58. Srivastava A, Lauwers GY. Pathology of non-infective gastritis. Histopathology. 2007 Jan. 50(1):15-29. [QxMD MEDLINE Link].

59. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002 Oct 10. 347(15):1175-86. [QxMD MEDLINE Link].

60. Yamamoto T, Matsumoto J, Shiota K, et al. Helicobacter heilmannii associated erosive gastritis. Intern Med. 1999 Mar. 38(3):240-3. [QxMD MEDLINE Link].

61. Morimoto M, Tamura S, Hayakawa T, et al. Phlegmonous gastritis associated with group A streptococcal toxic shock syndrome. Intern Med. 2014. 53(22):2639-42. [QxMD MEDLINE Link].

62. Min SY, Kim YH, Park WS. Acute phlegmonous gastritis complicated by delayed perforation. World J Gastroenterol. 2014 Mar 28. 20(12):3383-7. [QxMD MEDLINE Link].

63. Sugano K, Tack J, Kuipers EJ, et al, for the faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep. 64(9):1353-67. [QxMD MEDLINE Link]. [Full Text].

64. Shadifar M, Ataee R, Ataie A, et al. Genetic and molecular aspects of Helicobacter pylori in gastritis, pre- cancerous conditions and gastric adenocrcinoma. Gastroenterol Hepatol Bed Bench. 2015 Spring. 8(suppl 1):S15-22. [QxMD MEDLINE Link]. [Full Text].

65. Marginean MO, Melit LE, Mocanu S, Sasaran V. Ibuprofen, a potential cause of acute hemorrhagic gastritis in children - a case report. J Crit Care Med (Targu Mures). 2018 Oct. 4(4):143-6. [QxMD MEDLINE Link]. [Full Text].

66. Arif SH, Mohammed AA. Acute necrotising gastritis in a 14-year-old girl. BMJ Case Rep. 2019 May 19. 12(5):[QxMD MEDLINE Link].

67. Mahase E. FDA recalls ranitidine medicines over potential cancer causing impurity. BMJ. 2019 Oct 2. 367:l5832. [QxMD MEDLINE Link].

68. FDA Updates and press announcements on NDMA in Zantac (ranitidine). US Food and Drug Administration. Available at http://fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine. Accessed: July 13, 2020.

69. Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond). 2020 Jun. 52(6):381-90. [QxMD MEDLINE Link].

Sarah El-Nakeep, MD Associate Professor, Gastroentrology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Egypt

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Vincent W Yang, MD, PhD Simons Chair of Medicine, Professor, Departments of Medicine and Physiology and Biophysics, Renaissance School of Medicine at Stony Brook University

Vincent W Yang, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Gastroenterological Association, American Society for Clinical Investigation, Association of American Physicians

Disclosure: Nothing to disclose.

Waqar A Qureshi, MD, FRCP(UK), FACP, FACG, FASGE Professor of Medicine, Chief of Endoscopy, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

Waqar A Qureshi, MD, FRCP(UK), FACP, FACG, FASGE is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Gwendolyn Sarver

Disclosure: Nothing to disclose.

Mohammad Wehbi, MD Associate Professor of Medicine, Associate Program Director, Department of Gastroenterology, Emory University School of Medicine; Section Chief of Gastroenterology, Atlanta Veterans Affairs Medical Center

Mohammad Wehbi, MD is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, American Medical Association

Disclosure: Nothing to disclose.

Kamil Obideen, MD Assistant Professor of Medicine, Division of Digestive Diseases, Emory University School of Medicine; Consulting Staff, Division of Gastrointestinal Endoscopy, Atlanta Veterans Affairs Medical Center

Kamil Obideen, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Sunil Dacha, MBBS, MD House Staff, Division of Digestive Disease, Emory University School of Medicine

Sunil Dacha, MBBS, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Nicole M Griglione, MD Fellow in Gastroenterology, Department of Medicine, Emory University School of Medicine

Nicole M Griglione, MD is a member of the following medical societies: American Medical Association and Illinois State Medical Society

Disclosure: Nothing to disclose.

Richard H Snyder, MD Vice-Chair, Program Director, Department of Medicine, Norfolk General Hospital; Clinical Associate Professor, Department of Internal Medicine, East Virginia Medical School

Richard H Snyder, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article